Ligand Pharmaceuticals Incorporated

FRC's fair value estimate for Ligand Pharmaceuticals Incorporated, and the rating behind it. LGND last traded at $308.30, 30.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Ligand Pharmaceuticals Incorporated. Starting points for Ligand Pharmaceuticals Incorporated: P/E 30.8, EPS $9.83, beta 1.01 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Ligand Pharmaceuticals Incorporated. Ligand Pharmaceuticals Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Ligand Pharmaceuticals Incorporated. Trailing twelve-month EPS for Ligand Pharmaceuticals Incorporated stands at $9.83. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Ligand Pharmaceuticals Incorporated. Ligand Pharmaceuticals Incorporated has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Ligand Pharmaceuticals Incorporated valued side by side against its closest peers. Ligand Pharmaceuticals Incorporated is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Ligand Pharmaceuticals Incorporated, and how their positions are changing. At a $6.15B market value, institutional positions materially move Ligand Pharmaceuticals Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Ligand Pharmaceuticals Incorporated executives and directors. Shares of Ligand Pharmaceuticals Incorporated have traded between $93.58 and $212.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Ligand Pharmaceuticals Incorporated. Ligand Pharmaceuticals Incorporated is a $6.15B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Ligand Pharmaceuticals Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Ligand Pharmaceuticals Incorporated. Coverage tracks Ligand Pharmaceuticals Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.